These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34338755)

  • 1. Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study.
    Brink M; Kahle XU; Vermaat JSP; Zijlstra JM; Chamuleau M; Kersten MJ; Durmaz M; Plattel WJ; Lugtenburg PJ; Stevens W; Mous R; de Vries EGE; van der Poel MWM; Panday PVN; Huls G; van Meerten T; Nijland M
    Blood Adv; 2021 Aug; 5(15):2958-2964. PubMed ID: 34338755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial.
    Song Y; Zhou H; Zhang H; Liu W; Shuang Y; Zhou K; Lv F; Xu H; Zhou J; Li W; Wang H; Zhang H; Huang H; Zhang Q; Xu W; Ge Z; Xiang Y; Wang S; Gao D; Yang S; Lin J; Wang L; Zou L; Zheng M; Liu J; Shao Z; Pang Y; Xia R; Chen Z; Hou M; Yao H; Feng R; Cai Z; Zhang M; Ran W; Liu L; Zeng S; Yang W; Liu P; Liang A; Zuo X; Zou Q; Ma J; Sang W; Guo Y; Zhang W; Cao Y; Li Y; Feng J; Du X; Zhang X; Zhao H; Zhou H; Yu J; Sun X; Zhu J; Qiu L
    Adv Ther; 2021 Apr; 38(4):1889-1903. PubMed ID: 33751401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. REFLECT: prospective multicenter non-interventional study evaluating the effectiveness and safety of Sandoz rituximab (SDZ-RTX; Rixathon
    Welslau M; Kubuschok B; Topaly J; Otremba B; Wolff T; Bryn G
    Ther Adv Hematol; 2023; 14():20406207231183765. PubMed ID: 37492394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical outcomes of rituximab biosimilar CT-P10 (Truxima
    Lee K; Ha JY; Jung AR; Lee YS; Lee SW; Ryu JS; Chae EJ; Kim KW; Huh J; Park CS; Yoon DH; Suh C
    Leuk Lymphoma; 2020 Jul; 61(7):1575-1583. PubMed ID: 32290739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse large B-cell lymphoma.
    Shi Y; Song Y; Qin Y; Zhang Q; Han X; Hong X; Wang D; Li W; Zhang Y; Feng J; Yang J; Zhang H; Jin C; Yang Y; Hu J; Wang Z; Jin Z; Su H; Wang H; Yang H; Fu W; Zhang M; Zhang X; Chen Y; Ke X; Liu L; Yu D; Chen G; Wang X; Jin J; Sun T; Du X; Cheng Y; Yi P; Zhao X; Ma C; Cheng J; Chai K; Luk A; Liu E; Zhang X
    J Hematol Oncol; 2020 Apr; 13(1):38. PubMed ID: 32299513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
    Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
    Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
    Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
    Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
    Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
    Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
    Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
    Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
    Jurczak W; Ochrem B; Giza A; Zimowska-Curyło D; Górecki T; Boguradzki P; Knopińska-Posłuszny W; Stella-Hołowiecka B; Walewski J; Joks M; Wróbel T; Zaucha JM
    Pol Arch Med Wewn; 2015; 125(10):741-8. PubMed ID: 26334344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
    Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
    Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
    Purdum A; Tieu R; Reddy SR; Broder MS
    Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
    Younes A; Sehn LH; Johnson P; Zinzani PL; Hong X; Zhu J; Patti C; Belada D; Samoilova O; Suh C; Leppä S; Rai S; Turgut M; Jurczak W; Cheung MC; Gurion R; Yeh SP; Lopez-Hernandez A; Dührsen U; Thieblemont C; Chiattone CS; Balasubramanian S; Carey J; Liu G; Shreeve SM; Sun S; Zhuang SH; Vermeulen J; Staudt LM; Wilson W;
    J Clin Oncol; 2019 May; 37(15):1285-1295. PubMed ID: 30901302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
    Knight C; Hind D; Brewer N; Abbott V
    Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B-cell lymphoma in the rituximab era.
    Kumar A; Lunning MA; Zhang Z; Migliacci JC; Moskowitz CH; Zelenetz AD
    Br J Haematol; 2015 Dec; 171(5):776-83. PubMed ID: 26456939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
    J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.